Literature DB >> 10968244

Do recombinant human erythropoietin and iron supplementation increase the risk of retinopathy of prematurity?

C Romagnoli, E Zecca, F Gallini, P Girlando, A A Zuppa.   

Abstract

Comparing a group of infants treated with recombinant erythropoietin and iron supplementation to a group of control infants, no difference was observed concerning the transfusion need. The incidence of retinopathy of prematurity was significantly higher in the treated group. These data need to be confirmed in randomized controlled studies.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10968244     DOI： 10.1007/pl00008390

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN： 0340-6199            Impact factor:   3.183


  19 in total

1.  Erythropoietin and retinopathy of prematurity: a meta-analysis.

Authors:  Xu-Juan Xu; Hai-Yan Huang; Hong-Lin Chen
Journal:  Eur J Pediatr       Date:  2014-05-22       Impact factor: 3.183

2.  Multidose optimization simulation of erythropoietin treatment in preterm infants.

Authors:  Matthew R Rosebraugh; John A Widness; Peter Veng-Pedersen
Journal:  Pediatr Res       Date:  2012-02-15       Impact factor: 3.756

Review 3.  Epidemiology of Necrotizing Enterocolitis: New Considerations Regarding the Influence of Red Blood Cell Transfusions and Anemia.

Authors:  Vivek Saroha; Cassandra D Josephson; Ravi Mangal Patel
Journal:  Clin Perinatol       Date:  2018-12-12       Impact factor: 3.430

Review 4.  Retinopathy of prematurity: a review of risk factors and their clinical significance.

Authors:  Sang Jin Kim; Alexander D Port; Ryan Swan; J Peter Campbell; R V Paul Chan; Michael F Chiang
Journal:  Surv Ophthalmol       Date:  2018-04-19       Impact factor: 6.048

5.  Pharmacodynamically optimized erythropoietin treatment combined with phlebotomy reduction predicted to eliminate blood transfusions in selected preterm infants.

Authors:  Matthew R Rosebraugh; John A Widness; Demet Nalbant; Gretchen Cress; Peter Veng-Pedersen
Journal:  Pediatr Res       Date:  2013-11-11       Impact factor: 3.756

6.  Erythropoiesis Stimulating Agents Demonstrate Safety and Show Promise as Neuroprotective Agents in Neonates.

Authors:  Robin K Ohls; Robert D Christensen; John A Widness; Sandra E Juul
Journal:  J Pediatr       Date:  2015-04-25       Impact factor: 4.406

7.  Prediction of proliferative diabetic retinopathy with hemoglobin level.

Authors:  Baqiyyah N Conway; Rachel G Miller; Ronald Klein; Trevor J Orchard
Journal:  Arch Ophthalmol       Date:  2009-11

Review 8.  Darbepoetin Administration in Term and Preterm Neonates.

Authors:  Shrena Patel; Robin K Ohls
Journal:  Clin Perinatol       Date:  2015-05-23       Impact factor: 3.430

9.  A randomized, masked, placebo-controlled study of darbepoetin alfa in preterm infants.

Authors:  Robin K Ohls; Robert D Christensen; Beena D Kamath-Rayne; Adam Rosenberg; Susan E Wiedmeier; Mahshid Roohi; Conra Backstrom Lacy; Diane K Lambert; Jill J Burnett; Barbara Pruckler; Ron Schrader; Jean R Lowe
Journal:  Pediatrics       Date:  2013-06-17       Impact factor: 7.124

10.  Clinical Outcomes Related to the Gastrointestinal Trophic Effects of Erythropoietin in Preterm Neonates: A Systematic Review and Meta-Analysis.

Authors:  Anitha Ananthan; Haribalakrishna Balasubramanian; Shripada Rao; Sanjay Patole
Journal:  Adv Nutr       Date:  2018-05-01       Impact factor: 8.701
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.